Cargando…
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
BACKGROUND: Parkinson’s disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer’s disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576723/ https://www.ncbi.nlm.nih.gov/pubmed/37480401 http://dx.doi.org/10.1007/s00415-023-11875-z |
_version_ | 1785121176260968448 |
---|---|
author | Mizutani, Yasuaki Ohdake, Reiko Tatebe, Harutsugu Higashi, Atsuhiro Shima, Sayuri Ueda, Akihiro Ito, Mizuki Tokuda, Takahiko Watanabe, Hirohisa |
author_facet | Mizutani, Yasuaki Ohdake, Reiko Tatebe, Harutsugu Higashi, Atsuhiro Shima, Sayuri Ueda, Akihiro Ito, Mizuki Tokuda, Takahiko Watanabe, Hirohisa |
author_sort | Mizutani, Yasuaki |
collection | PubMed |
description | BACKGROUND: Parkinson’s disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer’s disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential tools for predicting abnormal pathological protein accumulation. We aimed to investigate the association between AD-related plasma biomarkers and cognitive decline in PD patients. METHODS: Plasma biomarkers were measured in 70 PD patients (49 with nondemented Parkinson’s disease (PDND) and 21 with Parkinson’s disease dementia (PDD)) and 38 healthy controls (HCs) using a single-molecule array. The study evaluated (1) the correlation between plasma biomarkers and clinical parameters, (2) receiver operating characteristic curves and areas under the curve to evaluate the discrimination capacity of plasma biomarkers among groups, and (3) a generalized linear model to analyze associations with Addenbrooke’s Cognitive Examination-Revised and Montreal Cognitive Assessment-Japanese version scores. RESULTS: Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups. Plasma beta-amyloid 42/40 and pholphorylated-tau181 indicated AD pathology in the PDD group, but plasma beta-amyloid 42/40 was increased in the PDND group compared with HCs and decreased in the PDD group compared with the PDND group. CONCLUSIONS: AD-related plasma biomarkers may predict cognitive decline in PD and uncover underlying mechanisms suggesting astrocytic pathologies related to cognitive decline in PD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11875-z. |
format | Online Article Text |
id | pubmed-10576723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-105767232023-10-16 Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease Mizutani, Yasuaki Ohdake, Reiko Tatebe, Harutsugu Higashi, Atsuhiro Shima, Sayuri Ueda, Akihiro Ito, Mizuki Tokuda, Takahiko Watanabe, Hirohisa J Neurol Original Communication BACKGROUND: Parkinson’s disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer’s disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential tools for predicting abnormal pathological protein accumulation. We aimed to investigate the association between AD-related plasma biomarkers and cognitive decline in PD patients. METHODS: Plasma biomarkers were measured in 70 PD patients (49 with nondemented Parkinson’s disease (PDND) and 21 with Parkinson’s disease dementia (PDD)) and 38 healthy controls (HCs) using a single-molecule array. The study evaluated (1) the correlation between plasma biomarkers and clinical parameters, (2) receiver operating characteristic curves and areas under the curve to evaluate the discrimination capacity of plasma biomarkers among groups, and (3) a generalized linear model to analyze associations with Addenbrooke’s Cognitive Examination-Revised and Montreal Cognitive Assessment-Japanese version scores. RESULTS: Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups. Plasma beta-amyloid 42/40 and pholphorylated-tau181 indicated AD pathology in the PDD group, but plasma beta-amyloid 42/40 was increased in the PDND group compared with HCs and decreased in the PDD group compared with the PDND group. CONCLUSIONS: AD-related plasma biomarkers may predict cognitive decline in PD and uncover underlying mechanisms suggesting astrocytic pathologies related to cognitive decline in PD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11875-z. Springer Berlin Heidelberg 2023-07-22 2023 /pmc/articles/PMC10576723/ /pubmed/37480401 http://dx.doi.org/10.1007/s00415-023-11875-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Mizutani, Yasuaki Ohdake, Reiko Tatebe, Harutsugu Higashi, Atsuhiro Shima, Sayuri Ueda, Akihiro Ito, Mizuki Tokuda, Takahiko Watanabe, Hirohisa Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease |
title | Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease |
title_full | Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease |
title_fullStr | Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease |
title_full_unstemmed | Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease |
title_short | Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease |
title_sort | associations of alzheimer's-related plasma biomarkers with cognitive decline in parkinson's disease |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576723/ https://www.ncbi.nlm.nih.gov/pubmed/37480401 http://dx.doi.org/10.1007/s00415-023-11875-z |
work_keys_str_mv | AT mizutaniyasuaki associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT ohdakereiko associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT tatebeharutsugu associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT higashiatsuhiro associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT shimasayuri associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT uedaakihiro associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT itomizuki associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT tokudatakahiko associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease AT watanabehirohisa associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease |